CS-101

GENETIC3 trials

Sponsors

CorrectSequence Therapeutics Co., Ltd, Children's Hospital of Fudan University

Conditions

Beta-Thalassemia

Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia

CompletedNCT06024876

CorrectSequence Therapeutics Co., LtdBeta-Thalassemia

Start: 2023-08-26End: 2025-07-01Updated: 2026-02-12

CS-101 in Patients With β-thalassemia

Enrolling by invitationNCT06328764

CorrectSequence Therapeutics Co., LtdBeta-Thalassemia

Start: 2024-03-19End: 2026-07-31Target: 10Updated: 2026-06-09

Unknown Phase

A Long-term Follow-up Study in Participants Who Received CS-101

RecruitingNCT06479616

Children's Hospital of Fudan UniversityBeta-Thalassemia

Start: 2024-06-18End: 2027-06-30Target: 5Updated: 2025-09-10

Related Papers

Clinical base editing for β-hemoglobinopathies across different genetic backgrounds.

2026-09-07

Clinical application of base editing for treating β-thalassaemia.

2026-04-08

Rapid, efficient and durable fetal hemoglobin production following CS-101 treatment in transfusion-dependent β-thalassemia participants: An autologous, ex vivo edited CD34+ stem cell product using the innovative transformer base editor (tBE)

Blood2025-11-03

Rapid, Efficient and Durable Fetal Hemoglobin Production Following CS-101 Treatment in Transfusion-Dependent β-Thalassemia Participants: An Autologous, Ex Vivo Edited CD34+ Stem Cell Product Using the Innovative Transformer Base Editor (tBE)

Blood2024-11-051 citations